Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Patrick A CoffieFrancois Dabis

Abstract

Our aim was to study the response to antiretroviral treatment among women exposed to single-dose nevirapine (NVP) and/or short-course zidovudine (ZDV; with or without lamivudine [3TC]) for the prevention of mother-to-child transmission of human immunodeficiency virus (HIV) infection. All HIV type 1-infected women who initiated antiretroviral treatment with stavudine or ZDV, 3TC, and NVP or efavirenz were eligible for the MTCT-Plus program in Abidjan, Ivory Coast. Exposed women had received either single-dose NVP alone or short-course ZDV (with or without 3TC) plus single-dose NVP during previous pregnancy. Genotypic resistance testing was performed at week 4 after delivery. Virologic failure was defined as a plasma HIV RNA level >500 copies/mL 12 months after initiation of antiretroviral treatment. Among 247 women who received antiretroviral treatment, 109 (44%) were unexposed; 81 had received short-course ZDV with 3TC, as well as single-dose NVP; 5 had received short-course ZDV plus 3TC; 50 had received short-course ZDV plus single-dose NVP; and 2 had received single-dose NVP alone. No ZDV mutation was detected in the 115 women whose specimens were available for genotypic testing; 11 (15.1%) of 73 women with 3TC exposure who w...Continue Reading

References

May 10, 2001·JAMA : the Journal of the American Medical Association·L MandelbrotUNKNOWN Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group
May 5, 2001·Journal of Virological Methods·C PasquierJ Izopet
Jun 28, 2002·Lancet·François Dabis, Ehounou René Ekpini
Nov 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pongsakdi ChaisilwattanaNisarat Opartkiattikul
Jul 13, 2004·The New England Journal of Medicine·Marc LallemantUNKNOWN Perinatal HIV Prevention Trial (Thailand) Investigators
Jul 13, 2004·The New England Journal of Medicine·Gonzague JourdainUNKNOWN Perinatal HIV Prevention Trial Group
Jul 23, 2005·Reproductive Health Matters·Landon MyerUNKNOWN Columbia University MTCT-Plus Initiative
Nov 15, 2005·AIDS·Jonathan ElfordGraham Hart
Jan 21, 2006·The Journal of Infectious Diseases·Marie-Laure ChaixUNKNOWN Agence Nationale de Recherches sur le SIDA Ditrame Plus Study Group
Aug 10, 2006·JAMA : the Journal of the American Medical Association·Edward J MillsDavid R Bangsberg
Jan 12, 2007·The New England Journal of Medicine·Shahin LockmanMax Essex
May 30, 2007·International Journal of Epidemiology·Elise ArrivéUNKNOWN Ghent Group on HIV in Women and Children

❮ Previous
Next ❯

Citations

Apr 11, 2009·Current HIV/AIDS Reports·Alice Marie Stek
Jan 17, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Glenda E Gray
Jun 14, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin S HirschDouglas D Richman
Nov 18, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Renaud BecquetFrançois Dabis
Feb 18, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marc LallemantUNKNOWN PHPT-4 Study Team
Jul 24, 2010·The Journal of Infectious Diseases·Sara Gianella, Douglas D Richman
Dec 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Russell B Van DykeUNKNOWN IMPAACT P1032 Protocol Team
Nov 17, 2009·AIDS·Roger ParedesUNKNOWN Women and Infants Transmission Study (WITS) Group
Oct 20, 2010·Antimicrobial Agents and Chemotherapy·Sihem BenaboudUNKNOWN TEmAA ANRS 12109 Study Group
Apr 9, 2009·BMC Infectious Diseases·Claire ThorneUNKNOWN Ukraine European Collaborative Study Group
Jan 1, 2013·Journal of the International AIDS Society·Lotus McDougalNancy Binkin
Nov 3, 2010·BJOG : an International Journal of Obstetrics and Gynaecology·S O MephamM-L Newell
Mar 3, 2011·International Journal of STD & AIDS·M G Bolhaar, A S Karstaedt
Jun 23, 2009·International Journal of STD & AIDS·N Agmon-LevinZ Sthoeger
Mar 26, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Nelly BriandUNKNOWN ANRS French Perinatal Cohort (ANRS EPF-CO-01)
Oct 20, 2010·Expert Review of Anti-infective Therapy·Anna CoutsoudisMairi Thomson
Jun 13, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Arthur J Ammann
Feb 25, 2015·AIDS·Susie HuntingtonUNKNOWN UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.